The Top 5 Biosimilar Articles for the Week of June 14

Video

Here are the top 5 biosimilar articles for the week of June 14, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 14, 2021.

Number 5: Same-day pegfilgrastim to combat febrile neutropenia in conjunction with myelosuppressive chemotherapy (CTX) is safe, investigators conclude in findings presented at the ASCO 2021 Annual Meeting.

Number 4: Investigators note a reduction in use of high-cost supportive care agents, suggesting that the value-based Oncology Care Model (OCM) is working.

Number 3: Postmarketing retrospective studies of the rituximab biosimilar (CT-P10, Truxima) demonstrate comparable safety and efficacy with the reference product for treatment of diffuse large B-cell lymphoma (DLBCL).

Number 2: In a column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.

Number 1: A Matrix Global Advisors report states that the European Union makes it far more difficult to obtain patents on biologics, reducing the likelihood of patent “thickets” that stifle competition.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
The Top 5 Biosimilar Articles for the Week of February 26
Ha Kung Wong, JD.
The Top 5 Biosimilar Articles for the Week of February 19, 2024.
Here are the top 5 biosimilar articles for the week of February 12, 2024.
Ha Kung Wong, JD
The top 5 biosimilar articles for the week of February 5, 2024.
The Top 5 Biosimilar Articles for the Week of January 29
Here are the top 5 biosimilar articles for the week of January 15, 2024.
The Top 5 Center for Biosimilars Articles for the Week of January 8, 2024.
Related Content
© 2024 MJH Life Sciences

All rights reserved.